Results 211 to 220 of about 4,566,680 (308)

Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC)

open access: yesEpilepsia, EarlyView.
Abstract Objective This randomized, double‐blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).
Dennis J. Dlugos   +74 more
wiley   +1 more source

‘BJUI Clinical Dilemma’: the overactive bladder

open access: yes
BJU International, EarlyView.
Oliver Gross   +7 more
wiley   +1 more source

Comprehensive assessment of erenumab efficacy in participants with high‐frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To evaluate the effect of erenumab treatment beyond monthly migraine days in patients with high‐frequency episodic migraine who did not respond to at least one previous migraine preventive treatment. Background Reduction in monthly migraine days has been the efficacy standard for migraine preventive treatments; however, it does not ...
Gabriel Paiva da Silva Lima   +11 more
wiley   +1 more source

Gepants for headache prevention in children and adolescents: A multicenter chart review study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Introduction There is an unmet need for safe, evidence‐based pharmacologic treatments for migraine prevention in children and adolescents. Rimegepant and atogepant, calcitonin gene‐related peptide receptor antagonists (gepants), have been shown to be efficacious and well‐tolerated preventive treatments in adults with migraine.
Lauren Shin   +9 more
wiley   +1 more source

Cytokine biomarkers and their relationship to symptoms and quality of life in people with HIV‐associated Kaposi sarcoma

open access: yesHIV Medicine, EarlyView.
Abstract Introduction Quality of life (QOL) is an essential component of care in people with HIV‐associated Kaposi sarcoma (HIV‐KS). Kaposi sarcoma herpes virus (KSHV) promotes cytokine expression and a dysfunctional inflammatory environment, contributing to KS pathogenesis and progression.
Fahmida Shaik   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy